Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
AbstractNiraparib (Zejula ™) is a PARP inhibitor which is approved for maintenance therapy in adults with advanced ovarian cancer in complete or partial response to platinum-based chemotherapy. In a placebo-controlled phase III trial in patients with newly diagnosed advanced ovarian cancer, niraparib significantly extended progression free survival in two predefined populations, namely a patient population with altered homologous-recombination DNA repair pathways [i.e. homologous-recombination deficiency positive (HRd)] and the overall trial population. A prespecified exploratory subgroup analysis indicated that nira par...
Source: Targeted Oncology - October 11, 2021 Category: Cancer & Oncology Source Type: research
Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer
AbstractOlaparib (Lynparza®) is a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor approved for first-line maintenance treatment in adults with advanced ovarian cancer who are in complete or partial response to first-line, platinum-based chemotherapy. Originally approved as monotherapy, olaparib is also approved to be administered in combination with bevacizumab in patients whose cancer is associated with homologous recombination deficiency (HRD), defined by either aBRCA1/2 mutation and/or genomic instability. In phase III trials, olaparib monotherapy significantly improved progression-free survival (PFS)...
Source: Targeted Oncology - October 8, 2021 Category: Cancer & Oncology Source Type: research
Correction to: Isatuximab: A Review of Its Use in Multiple Myeloma
(Source: Targeted Oncology)
Source: Targeted Oncology - October 8, 2021 Category: Cancer & Oncology Source Type: research
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
AbstractBreast cancer (BC) among Asians accounts for ~ 40% of the global BC burden. Differences in BC risk, presentation, tumor biology, and response to treatment exist between Asian and non-Asian patients; however, Asian patients are often under-represented in clinical trials. This narrative review summarizes the efficacy and safety of pharmacologica l therapies for BC in Asian populations, with a focus on outcomes in Asian versus non-Asian patients treated with chemotherapy, hormone therapy, anti-human epidermal growth factor receptor-2 targeted therapies, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, mammalian targ...
Source: Targeted Oncology - September 28, 2021 Category: Cancer & Oncology Source Type: research
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
AbstractActivating mutations in the epidermal growth factor receptor (EGFR) gene have been identified as key oncogenic drivers of non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso®) is an orally administered, third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) that is widely approved for the first-line treatment of advanced NSCLC with activatingEGFR mutations. In the pivotal phase III FLAURA trial, osimertinib significantly prolonged progression-free survival (PFS) and overall survival (OS) relative to first-generation EGFR-TKIs in patients with previously untreated,EGFR mutation-positive, advanced NSCLC. O...
Source: Targeted Oncology - September 26, 2021 Category: Cancer & Oncology Source Type: research
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
ConclusionsThis study demonstrated the proof-of-concept that prexasertib can be combined with cisplatin, cetuximab, and 5-fluorouracil. Schedule was a key determinant of the tolerability and feasibility of combining prexasertib with these standard-of-care agents. Reversible hematologic toxicity was the most frequent AE and was dose-limiting. Insights gleaned from this study will inform future combination strategies for the development of prexasertib and next-generation CHK1 inhibitors.ClinicalTrials.gov IdentifierNCT02124148 (date of registration 28 April 2014). (Source: Targeted Oncology)
Source: Targeted Oncology - September 24, 2021 Category: Cancer & Oncology Source Type: research
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
AbstractThe global incidence of malignant melanoma, the leading cause of skin cancer death, has steadily increased in recent years. Surgical excision is the treatment of choice for early-stage melanoma. However, 40 –60% of patients with high-risk melanoma or with nodal involvement eventually experience loco-regional relapse or tumor progression. Adjuvant therapy aims to reduce the rate of recurrence in radically operated high-risk patients with melanoma and thus improves survival. Interferon-α has long been the only approved drug for adjuvant melanoma therapy, despite an unclear survival benefit. The landmark success of...
Source: Targeted Oncology - September 23, 2021 Category: Cancer & Oncology Source Type: research
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience
ConclusionThe REP index is an independent prognostic factor for OS and PFS in patients with advanced HCC treated with regorafenib. (Source: Targeted Oncology)
Source: Targeted Oncology - September 7, 2021 Category: Cancer & Oncology Source Type: research
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ConclusionsThe magnitude of the statistically significant (P < 0.05) survival benefit of olaparib versus control observed in Cohort A of PROfound is likely to be underestimated if adjustment for treatment switching from control to olaparib is not conducted. The RPSFTM was considered the most plausible method, although further development and validation of rob ust methods to estimate the magnitude of impact of treatment switching is needed. (Source: Targeted Oncology)
Source: Targeted Oncology - September 3, 2021 Category: Cancer & Oncology Source Type: research
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab
ConclusionRCC patients with ≥ 1 BM who received I + N therapy had a relatively low response rate, PFS, and OS. Strategies to improve outcomes in this subset of patients are needed. (Source: Targeted Oncology)
Source: Targeted Oncology - August 11, 2021 Category: Cancer & Oncology Source Type: research
Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line
ConclusionsThe results of this retrospective study suggest that the use of BBs is associated with favorable outcomes for patients with mRCC treated with sunitinib or pazopanib in the first line. (Source: Targeted Oncology)
Source: Targeted Oncology - August 7, 2021 Category: Cancer & Oncology Source Type: research
Isatuximab: A Review of Its Use in Multiple Myeloma
AbstractIsatuximab (Sarclisa®; isatuximab-irfc in the USA) is an anti-CD38 monoclonal antibody (mAb) approved for use in the treatment of adults with multiple myeloma (MM): in combination with pomalidomide and dexamethasone for those with relapsed and refractory MM (RRMM) who have received ≥ 2 prior therapies, including lenalidomide and a proteasome inhibitor; and in combination with carfilzomib and dexamethasone for those with relapsed MM who have received ≥ 1 prior therapy. In phase III studies, the addition of isatuximab to pomalidomide and dexamethasone significantly prolo nged progression-free survival (PFS) ...
Source: Targeted Oncology - August 5, 2021 Category: Cancer & Oncology Source Type: research
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
ConclusionsThis real-world analysis demonstrated that HR+/HER2 ‒ MBC patients were more likely to respond to PAL+LET compared to LET. These findings further showed the effectiveness of PAL+LET therapy in the real-world setting and support the combination as a standard of care for MBC.Study RegistrationPfizer; NCT04176354; registered November 25, 2019 (Source: Targeted Oncology)
Source: Targeted Oncology - August 2, 2021 Category: Cancer & Oncology Source Type: research
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
ConclusionsOur data show that cabozantinib is active in pretreated patients with sarcomatoid renal cell carcinoma. Biomarkers are needed in this field to select patients for multi-kinase inhibitors or other options. (Source: Targeted Oncology)
Source: Targeted Oncology - August 2, 2021 Category: Cancer & Oncology Source Type: research
Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation
ConclusionsJAK1i+ ATRA lead to decreases in cell cycle followed by myeloid differentiation and cell death in human leukemias. These findings highlight potential uses of ATRA-based differentiation therapy of non-M3 human leukemia. (Source: Targeted Oncology)
Source: Targeted Oncology - July 29, 2021 Category: Cancer & Oncology Source Type: research
